TABLE 1.

The effects of coadministration of pemafibrate on the HMG‐CoA reductase inhibitory activity of plasma samples in participants treated with simvastatin.

Parameter	Treatment at the time of blood sampling	n	Active HMG‐CoA reductase inhibitors in plasma samples before base hydrolysis a	Total HMG‐CoA reductase inhibitors in plasma samples after base hydrolysis a
C max (ng‐Eq/mL)	Simvastatin alone	18	26.2 (60.7); 25.8 [18.3–35.5]	118 (73.3); 129 [81–157]
	With pemafibrate	18	28.0 (41.8); 31.1 [22.4–42.4]	123 (41.7); 138 [96–149]
AUC0‐τ (ng‐Eq·h/mL)	Simvastatin alone	18	180 (63.9); 188 [115–211]	441 (42.9); 451 [335–595]
	With pemafibrate	18	131 (43.7); 133 [106–185]	413 (28.8); 443 [385–486]

Note: Data are presented as geometric mean (coefficient of variation); median [interquartile range].

^a The concentration of active and total HMG‐CoA reductase inhibitors were expressed as simvastatin acid equivalents by measuring the inhibitory activity of plasma samples before and after base hydrolysis. ²⁴